Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Simon Behar

Gastroenterology Miami, FL Medical Doctor

NPI 1982706958 CMS profile 180837

8950 N Kendall Dr Ste 306, Miami, FL 33176

Open in the dashboard

General payments

$17,800

1,185 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Simon Behar of Miami, FL is reported in the CMS Open Payments database as having received $17,800 across 1,185 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,512 186
2024 General $2,568 149
2023 General $2,624 188
2022 General $3,248 214
2021 General $2,779 211
2020 General $1,177 83
2019 General $1,891 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Simon Behar
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Simon Behar were reported at $3,512. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Simon Behar Gastroenterology median Middle half National median
2019 $1,891 $417 $126–$1,100 $163
2020 $1,177 $224 $74–$624 $114
2021 $2,779 $352 $106–$1,054 $132
2022 $3,248 $448 $129–$1,270 $149
2023 $2,624 $533 $150–$1,390 $160
2024 $2,568 $605 $160–$1,606 $164
2025 $3,512 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,961 191 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,379 216 payments
  3. Janssen Biotech, Inc. $2,256 131 payments
  4. QOL Medical, LLC $1,554 116 payments
  5. Celgene Corporation $768 66 payments
  6. Genzyme Corporation $732 30 payments
  7. Gilead Sciences, Inc. $682 39 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $589 32 payments
  9. RedHill Biopharma Inc. $553 57 payments
  10. Ironwood Pharmaceuticals, Inc $517 37 payments
  11. Other $4,808 270 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,349 1,179 payments
  2. Education $451 6 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,909 166 payments
  2. STELARA $1,586 97 payments
  3. CREON $1,041 71 payments
  4. LINZESS $1,020 73 payments
  5. HUMIRA $848 47 payments
  6. RINVOQ $756 46 payments
  7. TREMFYA $746 35 payments
  8. DUPIXENT $732 30 payments
  9. Sucraid $729 60 payments
  10. ZEPOSIA $725 63 payments
  11. Other $9,674 690 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,818

Median for Gastroenterology: 569

Drug cost

$743,626

Median for Gastroenterology: $104,976

Branded share of claims

31.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 90 $285,289
Zenpep Lipase/Protease/Amylase Brand 46 $199,609
Xifaxan Rifaximin Brand 19 $54,360
Linzess Linaclotide Brand 52 $41,095
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 182 $31,592
Mesalamine Generic 72 $29,890
Budesonide Er Budesonide Brand 29 $24,655
Dexilant Dexlansoprazole Brand 16 $12,479
Mesalamine Er Mesalamine Brand 24 $10,405
Dexlansoprazole Dr Dexlansoprazole Brand 21 $9,413

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$45,937

Medicare's payments for the services billed

Medicare patients

238

Average age 74

Services billed

677

134 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 46%
Diabetes 42%
Depression 34%
Chronic kidney disease 33%
Atrial fibrillation 29%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
$326 — —
STELARA
$289 — —
DUPIXENT
$220 — —
LINZESS
$142 52 —
TREMFYA
$138 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

1,185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record